These payloads block the systems cells use to cope with damaged DNA. One strategy puts a damage-causing drug and a repair-checkpoint inhibitor on the same antibody.
DNA damage response inhibition is a payload mechanism only when the inhibitor is carried by the conjugate. CLIO-8221 combines exatecan with the ATR inhibitor berzosertib on a HER2-directed antibody. Its published trial-design abstract describes preclinical rationale and a phase 1/2 study, not clinical proof that the combination overcomes resistance. Giving a separate PARP, ATR or WEE1 inhibitor alongside an antibody-drug conjugate is a combination regimen, not evidence of that inhibitor being an attached payload.
Showing the technology this term belongs to: Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/